Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1369 articles with Gilead Sciences, Inc.
It has been noted that a number of billionaires—at least six—who are fifty years or older in age, have been investing in health care and longevity-related startup companies.
Gilead Lawsuits: California HIV Patients File Class Action and Personal Injury Cases Over Key HIV Drug
Legal actions filed by patients with HIV from Los Angeles, San Diego & Marin Counties target Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
Webcast Available Through Gilead Corporate Website
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
The two companies will use Verity’s Immunoscape platform to profile the molecular characteristics of inflammatory diseases.
At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.
Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.
Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the second quarter of 2018.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2018.
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
Gilead Sciences, Inc. and Verily Life Sciences LLC announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.
Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Biktarvy®.
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.